Obama and his corporate Democrats despise liberal/progressives.<quoted text>
There ya go again, thinkin' linear again. Politics is three dimensional. You has Fiscal, Religion and Social issues and Libertarians are ultra-conservative on fiscal issues but ultra-liberal on social and religious issues.
And Obama is a flaming progressive. His goal is that the federal government to control every issue.
Federal law adopted "under Tommy Thompson's watch" prohibits the government from negotiating for "better prices" on prescription drugs for senior citizens / August 15th, 2012 / http://tinyurl.com/98o296v
Health Care Bill Brings Debate Over Importing Drugs
December 11, 2009 / http://tinyurl.com/b93tneq
As a presidential candidate, Barack Obama said that the United States should be able to import prescription drugs (PDF) from other countries, where they are sold at significantly cheaper prices. He even co-sponsored a Senate bill proposing such an idea.
Now, however, his administration is warning against this idea. And a divide among Democrats on the issue is holding up the health care debate in the Senate.
Sen. Byron Dorgan (D-N.D., at left) on Tuesday introduced an amendment to the Senate health care bill that would enable the importation of cheaper prescription drugs into the U.S. The plan, Dorgan says, would save the federal government $19 billion over 10 years and save the American people about four times that much.
Nineteen other senators, including four Republicans, immediately offered their support to the plan./ http://www.cbsnews.com/8301-503544_162-596779...
Fiscal Footnote: Big Senate Gift to Drug Maker
January 19, 2013 / http://tinyurl.com/byc4mmb
WASHINGTON Just two weeks after pleading guilty in a major federal fraud case, Amgen, the worlds largest biotechnology firm, scored a largely unnoticed coup on Capitol Hill: Lawmakers inserted a paragraph into the fiscal cliff bill that did not mention the company by name but strongly favored one of its drugs.
The language buried in Section 632 of the law delays a set of Medicare price restraints on a class of drugs that includes Sensipar, a lucrative Amgen pill used by kidney dialysis patients.
The provision gives Amgen an additional two years to sell Sensipar without government controls. The news was so welcome that the companys chief executive quickly relayed it to investment analysts. But it is projected to cost Medicare up to $500 million over that period.